Cost-Effectiveness Analysis of the Treatment of Ventilator-Associated Pneumonia with Linezolid or Vancomycin in Spain

References

• National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001; 29: 404–21.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lerma F, Palomar M, Olaechea P, Insausti J, Bermejo B, Cerda E and Grupo de estudio de vigilancia de infecci6n nosocomial en UCI. Estudio nacional de vigilancia de infecci6n nosocomial en unidades de cuidados intensivos. Informe del atio 2001. Med Intensiva 2003; 27: 13–23.
   Google Scholar
• Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281–8.
   PubMed Web of Science ®Google Scholar
• Papazian L, Bregeon F, Thirion X, et al. Effect of venti-lator-associated pneumonia on mortality and morbidity. Am J Resp Crit Care Med 1996; 154: 91–7.
   PubMed Web of Science ®Google Scholar
• Bercault N, Boulain T. Mortality rate attributable to ven-tilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001; 29: 2303–309.
   PubMed Web of Science ®Google Scholar
• Álvarez Lerma F, Torres A, Rodriguez de Castro F et al. Recomendaciones para el diagnOstico de la neumonia aso-ciada a ventilaciem mecánica. Available in URL: http://www.seimc.org/geih/doc3.htm (May 2004).
   Google Scholar
• Jordá Marcos R, Torres Marti A, Ariza Cardenal FJ, et al. Recomendaciones para el tratamiento de la neumonia intrahospitalaria grave. Med Intensiva 2004; 28: 262–78.
   Google Scholar
• Palomar Martinez M. Evoluciem de los marcadores de multirresitencia. In: Estudio Nacional de Vigilancia de Infecciem Nosocomial en UCI (ENVIN-UCI). In: Jarpyo SA (ed) Informe de la evoluciem de la incidencia y caracteristicas de las infec-clones nosocomiales adquiridas en Servicios de Medicina Intensiva (1994-2001). Grupo de Trabajo de Enfermedades Infecciosas de la SEMICYUC (GTEI-SEMICYUC). Madrid: Jarpyo SA, 2002: 113–27.
   Google Scholar
• Carmona PM, Romã E, Monte E, Garcia J, Gobernado M. Papel de linezolid en terapeutica antimicrobiana. Enferm Infecc Microbiol Clin 2003; 21: 30–41.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-posi-tive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388–94.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH, Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25: 980–92.
   Google Scholar
• Rubinstein E, Cammarata S, Oliphant T, Wunderink R, Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospi-talized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402–12.
   Google Scholar
• Milne RJ. Pharmacoeconomic models in disease man-agement. A guide for the novice or the perplexed. Dis Manage Health Outcomes Res 1998; 4: 119–34.
   Google Scholar
• Shorr AF, Susla GM, Kollef MH. Linezolid for treat-ment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004; 32: 137–43.
   PubMed Web of Science ®Google Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 819–29.
   Web of Science ®Google Scholar
• Qartin AA, Schein RM, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997; 277: 1058–63.
   Google Scholar
• Hamel MB, Phillips RS, Davis RB, et al. Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med 2000; 109: 614–20.
   PubMed Web of Science ®Google Scholar
• Rovira J, Añtorianzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 1995; 8: 245–52.
   Google Scholar
• Canadian Coordinating Office for Health Technology Assessment. Guideline for economic evaluation of pharmaceu-ticals: Canada. 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997.
   Google Scholar
• Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR. Principles of good practice for decision analytic modeling in health-care evalua-tion: report of the ISPOR Task Force on good research prac-tices - modeling studies. Value in Health 2003; 6: 9–17.
   PubMed Web of Science ®Google Scholar
• Gisbert R, Brosa M. Base de datos de costes sanitarios. Version 1.5. Barcelona: Soikos, 2004.
   Google Scholar
• Johannesson M. Theory and methods of economic evaluation of health care. Dordrecht: Kluwer Academic Publishers, 1996.
   Google Scholar
• Base de datos de medicamentos. Consejo General de Colegios Oficiales de Farmaceuticos. Available in URL: http://www.portalfarma.com/home.nsf (May, 2004).
   Google Scholar
• Abad F, Calbo F, Zapater P, Rodriguez-Vilanova F, Garcia-Perez LE, Sacristán JA. Comparative pharmacoeco-nomic study of vancomycin and teicoplanin in intensive care patients. Int J Antimicrob Agents 2000; 15: 65–71.
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnologia sanitaria eficiente en España? Gaceta Sanitaria 2002; 16 (4): 334–43.
   PubMedGoogle Scholar
• Alvarez-Lerma F, Ucio P, Gonzalez V, Blanco A, Leem C and Grupo de estudio de infecciones por CGP. Linezolid vs. glycopeptides for the treatment of suspected or know gram-positive cocci infections. Intensive Care Med 2003; 29 (suppl 1); 569 (abs 254).
   Google Scholar